

Axinn Successfully Obtains Dismissal for Zydus Pharmaceuticals

A decorative graphic on the right side of the page features a light blue and white grid pattern that curves and flows downwards, resembling a stylized ribbon or a modern architectural element.


NEWS | 1 MIN READ

October 13, 2015

Axinn successfully obtained the dismissal of an amended complaint brought against its client, Zydus, in ongoing patent litigation concerning generic versions of Abilify® (aripiprazole). Otsuka markets Abilify® and filed an amended complaint against Zydus adding infringement allegations related to U.S. Patent No. 8,759,350.

Axinn attorneys filed a motion to dismiss the allegations relating to the '350 patent, and the U.S. District Court for the District of New Jersey granted this motion on October 13. Specifically, the Court dismissed Otsuka's direct and contributory infringement claims with prejudice. The Court also dismissed Otsuka's induced infringement claim without prejudice, concluding that the amended complaint did not offer allegations directed at intentional or specific actions necessary to plead induced infringement. Otsuka may amend its induced infringement claim, but the Court cautioned Otsuka to consider "the litany of evidentiary deficiencies identified in the Court's TRO Opinion." Axinn previously succeeded in obtaining a denial of Otsuka's TRO motion on the '350 patent in April.

Related People



Jason Murata

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST

- Merger Remedies Back in Vogue Under Trump

MEDIA MENTIONS ANTITRUST

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved